Who the PD-L1 Expression Assay can help

PD-L1 (Programmed death-ligand 1) has been identified as an immunosuppressive driver and an important facilitator for tumor growth and metastasis. PD-L1 has been detected in up to 50 percent of all human cancers, making it a major focus of therapeutic research and treatment.

 
PD-L1 Testing Recommendations

PD-L1 Testing Recommendations

 

More Information About the PD-L1 Expression Test

+ How the test works

Via a simple blood draw, the test analyzes Circulating Tumor Cells (CTC) for PD-L1 expression and can be used to help identify candidates that may benefit from immunotherapy treatment. Patients expressing PD-L1 on tumor cells have experienced substantial clinical benefit with new FDA-approved checkpoint inhibitors, such as Keytruda, Opdivo and Tecentriq.


+ What your doctor receives

Within 3-7 days, your doctor will receive a detailed report on your PD-L1 expression. From this, decisions to treat with immunotherapy drugs can be determined with confidence. We are proud to offer the most clinically relevant and actionable reports available.


+ How often to re-test

The ideal testing frequency will vary by patient. Your doctor can create a schedule that’s right for you.


+ Will insurance cover it?

Cynvenio accepts most insurance plans, and will directly bill the insurance company. Through our ClearBilling program, we also offer several options to help non-insured and underinsured patients. Learn more.


Request Information

Name *
Name
 

†Adams DL, et al. Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy. Clinical Cancer Research (2017).

/*This is to open gallery links in new window*/